Quality of life one year after chemoradiotherapy for localized primary gastric diffuse large B-cell lymphoma.
We assessed the quality of life (QOL) at least one year after sequential chemoradiotherapy for the treatment of localized gastric diffuse large B-cell lymphoma (DLBCL). We used the EORTC Quality of Life Questionnaire for Stomach Cancer (EORTC QLQ-STO22). Among the 45 patients available at the one-year follow-up after radiation therapy, 40 patients completed the EORTC QLQ-STO22 questionnaire. Their median age was 54.5 (range, 20-70 years). Social functioning was most adversely affected among the respondents with a score of 59, whereas other functions and the global scales were preserved above a score of 70 by linearly transformed values. Fatigue, the financial impact and specific emotional problems such as "thinking about their illness" (STO-ANX) and "worry about weight loss or future health" (STO-BI) were persistently bothersome for some patients. Other stomach-related symptoms such as dysphagia, pain, or reflux were negligible at 1 year after treatment. Therefore, this organ-preserving combined approach was effective for the maintenance of the QOL and minimization of stomach abnormalities in patients with gastric lymphoma.
Kim
Won Seog
WS
Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Park
Yeon Hee
YH
Lee
Se-Hoon
SH
Ryoo
Baek-Yeol
BY
Yang
Sung Hyun
SH
Lee
Seung-Sook
SS
Kim
Mi Sook
MS
Kim
Kihyun
K
Park
Keon Woo
KW
Im
Do Hyoung
DH
Kang
Jung Hun
JH
Lee
Jeeyun
J
Ko
Young H
YH
Ahn
Yong Chan
YC
Lim
Do Hoon
DH
Park
Keunchil
K
Bang
Soo-Mee
SM
D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000523:psychology* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D011878:Radiotherapy; D013274:Stomach Neoplasms / Q000523:psychology* / Q000628:therapy*; D011795:Surveys and Questionnaires
D000970:Antineoplastic Agents